News | January 07, 2024
AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan
The deal includes upfront payments, milestone payments and ongoing royalties
The deal includes upfront payments, milestone payments and ongoing royalties
The company has received five final approvals
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
AMI to become part of Enpro’s Sealing Technologies Segment
Sirius JV will be owned 51% by Sirius and 49% by Adani
US FDA approval based on NEURO-TTRansform Phase III results
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Subscribe To Our Newsletter & Stay Updated
